univers coverag
calendar event
medacorp puls call get straight trend dental edt
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet intern societi research iser biennial meet
pamrevlumab profil compel ipf execut pt
bottom line increasingli confid profil potenti second
proprietari drug pamrevlumab anti-ctgf account compani ev
idiopath pulmonari fibrosi ipf note assess diseas competit regulatori
develop landscap pamrevlumab ipf find drug profil certainli
highli competit incumb medicin drug develop timelin like
longer previous forecast particularli sinc compani yet announc
pivot trial design time updat launch timelin increas probability-
of-success po pamrevlumab ipf rais price target
reiter outperform rate schedul announc design pivot
trial pamrevlumab ipf sometim offer long-term growth opportun
compani also near-term opportun stock re-valu review design result
major trial approv drug potenti competitor conclud pamrevlumab
highli competit profil term efficaci toler eas dose although pivot trial
like take year complet believ pamrevlumab well posit lead next wave
pamrevlumab competit efficaci toler profil approv drug
expect pivot trial design similar competitor
whatev pivot trial design adopt risk given complic work around
exist drug regardless design need massiv expand network center achiev
adequ enrol reason pace
push launch timelin rais po pt
cfo retir usher promot anim health chief
bottom line afternoon announc retir tim guttman cfo jame cleari
current presid global commerci servic anim health appoint
cfo mr guttman expect remain advisori capac follow
retir though mr guttman sinc serv cfo
sinc believ member manag team signific oper
industri knowledg appear prepar smooth transit mr cleari
formerli serv ceo mwi veterinari suppli join compani acquir
mwi mr cleari promot assum respons pharma
commerci servic addit overse anim health busi robust
experi anim health believ mr cleari good compliment ceo steven colli
extens pharma background remain confid posit outlook stock
addit news mr guttman retir compani re-affirmed guidanc
link press releas link
ceo transit indic us fundament stronger pt
 methodolog sale
bottom line tonight market close announc patrick sullivan would step
ceo end year pass baton current shacey petrov januari
hindsight clearli success plan work time --
least sinc petrov took role octob nearli two year ago petrov
involv day-to-day oper also becom increasingli visibl
street last two year confirm ir success plan fact
place -- achiev mileston hope turn busi
around -- sullivan step four year line commit board
year hire conjunct today announc reiter sale
guidanc importantli us transit indic
fundament stronger ever hand petrov -- someon
proven capabl manag busi case firmli believ
sullivan would stay least anoth year ensur foundat stabl
reiter op pt
zane departur overli surpris
bottom line though zane burk departur signific loss compani
stalwart two decad believ size scale cultur ensur
busi navig transit leadership view mr burk may leav
passed-ov appoint brent shafer ceo februari
believ departur signal anyth compani health press report
morn re-affirm prior guidanc promot john peterzalek assum mr
link press releas link
fda say aa pomp pivot studi initi pt
bottom line announc fda like ema endors acceler
approv aa pathway at-gaa pomp diseas base current set clinic data
believ investor sentiment larg baked-in neg outcom although remov
potenti upsid catalyst still pressur stock pre-open previous assign
probabl market entri push commerci launch
po give hope complet fda could acquiesc go
forward compani continu analyz present addit data on-going
studi time adjust model decreas pt remain
op-rat
revenu mm ep
bottom line reiter convict plan retir ceo milton
johnson mr johnson replac presid hazen highli respect
street natur successor milton johnson mr johnson retir ceo effect
decemb remain chairman board sharehold meet
april current board member thoma frist replac mr johnson new chairman
purchas file make lot sens
bottom line morn walgreen announc purchas patient prescript file
pharmaci inventori fred fred nr store account
addit revenu store file provid lost interest incom cash
estim file add annual ep gener think
deal make lot sens effect buy pharmaci volum visit fred
without purchas entir store infrastructur minim integr
risk deal may respons op market share gain bp
asset purchas follow acquisit store roughli one year ago
help bolster compani us retail divis whose revenu grew y/i
transfer patient file expect begin complet
could cch cellulit meaning opportun endo
ev/ebitda multipl
leadership seri busi sourc lt upsid
ev/sal multipl sale
outlook still conserv consum growth engin invest dx pt
reason posit bipolar phase pt
 methodolog blend revenu multipl dcf analysi
discount rate termin growth rate
posit transform continu stock seem fairli valu
adjust ep
sept teva fremanezumab anti-cgrp prevent migrain pdufa
manag remain confid time approv fremanezumab
septemb pdufa date follow recent issuanc new letter fda
celltrion facil discuss medacorp current good manufactur
practic cgmp specialist continu believ low likelihood
observ made latest letter juli inspect highlight issu like
impact product qualiti patient safeti result believ celltrion unlik
yet made adequ progress resolv outstand warn letter
link recent analysi latest letter
obsv nolasiban oral oxytocin receptor antagonist assist
nolasiban target ivh market larg grow need treatment
implant phase data demonstr direct improv
pregnanc rate day day pregnanc show stat sig improv
pool data
believ data encourag may even suffici approv eu
along posit sub-group analysi ph
look manag provid greater regulatori clariti requir approv
us eu
believ risk-reward skew upsid ahead upcom catalyst
addit look live birth rate data implant posit
go long way improv commerci potenti
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es
also tumor cohort object respons rate durat
respons data essenti plan nda file
partner lysa present phase ib safeti pk data combin
tazemetostat chemotherapi r-chop front-lin diffus larg cell lymphoma
dlbcl cohort includ patient stratifi mutat
statu one two on-going tazemetostat trial dlbcl compani
recent announc de-priorit studi indic
tazemetostat clinic program still partial hold us franc germani
prompt respons regulatori author resolut clinic hold critic
time enrol patient follicular lymphoma trial project snda
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
pdufa teva fremanezumab cgrp migrain
fda adcom neurolog devic panel medic devic
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefenacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
chines societi clinic oncolog zlab
data present
zlab brivanib ph ii result
european societi retina specialist euretina nite
american colleg clinic pharmacolog
intern associ studi lung cancer
feder surgeri obes metabol disord
american academi implant dentistri
american societi head neck radiolog
european societi paediatr endocrinolog
american societi bone miner research asnd cmta
american academi otolaryngolog head neck surgeri aao-hnsf annual
american societi human genet arql
european societi medic oncolog adap imdz iph
go live az
model model recent updat
pleas contact leerink repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
